Non-invasive monitoring in pediatric kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new way to monitor children and young adults who have received a kidney transplant. It aims to personalize their anti-rejection medications using less-invasive checks, instead of relying on frequent biopsies. It could reduce discomfort and improve long-term kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were under 21 years old when you received your kidney transplant.
- You received only one kidney (either from a living donor or a deceased donor).
- If you are a female of childbearing age, you must have a negative pregnancy test and not be pregnant.
- You and your legal guardian agree to the study procedures and can sign a consent form.
- You must be covered by French health insurance (including AME).
- Your doctor plans to do a routine surveillance biopsy of your kidney.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a simple blood test that looks for donor DNA can help doctors take better care of kidney transplant patients. It may help detect early signs of rejection and guide treatment decisions.
This study looks for small pieces of kidney DNA in the blood of kidney transplant patients. It aims to improve monitoring of transplant health.
This study looks for pieces of kidney DNA in the blood of people who have a kidney transplant and need a biopsy. The goal is to see if this test can help doctors know if the kidney is being rejected without needing a biopsy.
This study tests a new blood test (called cfDNA) that may help doctors detect early signs of kidney transplant rejection before problems develop. The goal is to help keep your transplanted kidney healthy longer by catching issues early.
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
This trial uses a personalized approach (including tacrolimus medication planning and monitoring) to better understand how a kidney transplant is doing. It may help your transplant team tailor care to your kidney function over time.
Hear when a new Pediatric Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.